We would like to introduce a study published by our client using our proprietary non-alcoholic steatohepatitis (NASH) model called STAM™ (Ikewaki et al., bioRxiv, 2021).

In this study, the authors evaluated how the single or combined consumption of two β-glucans derived from the AFO-202 and N-163 strains of black yeast, Aureobasidium pullulans, affected the progression of NASH in the STAM™ model.

Would you like to use the STAM™ model to test the efficacy of your compound in monotherapy or combination therapy?　We can use our years of experience to offer you a study design that is tailored to suit your needs.　If you are interested in using our STAM™ model, please do not hesitate to reach out!